Understanding MRD Testing

Core Conclusion

Minimal residual disease (MRD) testing detects down to 1 myeloma cell in 100,000 (10⁻⁵) or 1,000,000 (10⁻⁶), where maintaining confirmed MRD negativity across 12 consecutive months predicts 5-year progression-free survival exceeding 80%.

Detailed Points

• (1) The Definition of MRD (Finding the "1 in a Million"): Even after standard blood and urine tests show that you have reached a Complete Response (CR) and your symptoms have disappeared, a tiny number of myeloma cells might still survive and hide inside your body. Minimal Residual Disease (MRD) testing looks for these leftover cells at a microscopic level. Being "MRD-negative" means that using highly sensitive tests, doctors cannot find even 1 single myeloma cell hidden among 100,000 (a sensitivity of $10^{-5}$) or even 1,000,000 (a sensitivity of $10^{-6}$) normal bone marrow cells.

• (2) Testing Methods (NGF vs. NGS): Because standard tests are not sensitive enough, MRD is currently measured using a sample from a bone marrow biopsy. The two main, highly validated technologies used are:

  • NGF (Next-Generation Flow Cytometry): This test (often using the "EuroFlow" standard) scans the bone marrow to identify phenotypically abnormal, cancerous plasma cells based on their surface markers.
  • NGS (Next-Generation Sequencing): This test (such as the clonoSEQ or LymphoSIGHT assay) looks at the actual DNA inside the cells. It searches for the unique genetic "fingerprint" or DNA sequencing reads of your specific myeloma cells.
  • Note on Imaging: Because myeloma can also live outside the bone marrow, doctors often pair these marrow tests with highly sensitive imaging (like a PET-CT or MRI) to confirm you are "Imaging plus MRD-negative".

• (3) When MRD Testing Should Be Performed: MRD testing is not used at the very beginning of your journey; it is only initiated when your doctor suspects you have reached a Complete Response (CR). It is typically checked at major milestones: after your initial induction therapy, after an autologous stem cell transplant (usually around day 100), after consolidation therapy, and periodically during maintenance therapy. To achieve what doctors call "Sustained MRD negativity," your tests must remain completely negative for a minimum of 1 year apart.

• (4) Its Role as a Prognostic Marker (What MRD-negative means for you): Achieving MRD negativity is fantastic news. It is one of the strongest predictors of a favorable prognosis. Large clinical studies confirm that patients who achieve MRD negativity—and especially those who sustain it for 12 months or longer—enjoy a significantly longer Progression-Free Survival (time without the disease returning) and Overall Survival. In fact, it is such a powerful indicator of deep healing that the U.S. FDA recently recommended MRD negativity as an official endpoint for accelerating the approval of new myeloma drugs.

• (5) Does MRD Negativity Dictate Treatment Cessation? It is completely natural to wonder, "If my test shows zero cancer cells, can I stop taking my maintenance medications?" Currently, the clinical guidelines strongly state that it is premature to base treatment decisions (like stopping therapy) solely on MRD results outside of a clinical trial. There is not yet enough evidence to prove that stopping treatment is safe just because a test is MRD-negative, and some patients remain MRD-positive but live stable, symptom-free lives for years. While recent data does support investigating whether maintenance therapy can be stopped after 3 years of sustained MRD negativity for standard-risk patients, this must only be done carefully within a research setting or under expert guidance. For now, you should continue your maintenance therapy to keep the myeloma deeply asleep.

The above content is sourced from the following references

• EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
• Experts' consensus on the definition and management of high risk multiple myeloma
• First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma
• IMF Patient Handbook
• MMRF Learn Your Labs
• MMRF Treatment Overview
• NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma
• Singapore Myeloma Study Group consensus guidelines for the management of patients with newly diagnosed multiple myeloma